"Glycomine's progress towards delivering the first disease-modifying therapy for a rare genetic disorder was bolstered by a $115 million Series C funding round."
"This funding will support a randomized, placebo-controlled Phase 2b trial for GLM101, aimed at serving patients with PMM2-CDG."
Glycomine, Inc. has successfully raised $115 million in a Series C funding round led by significant investors to propel its lead candidate GLM101 into a Phase 2b clinical trial. The funding will facilitate a randomized, placebo-controlled study aimed at testing the safety and efficacy of GLM101, a therapy designed to treat PMM2-CDG, a rare, life-threatening genetic disorder. Initial results from ongoing trials have already shown promising outcomes, indicating a transformative potential for patients affected by this condition, marking a significant step towards addressing an unmet medical need in the orphan disease sector.
Read at Silicon Valley Journals
Unable to calculate read time
Collection
[
|
...
]